Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ALXO

ALX Oncology (ALXO)

ALX Oncology Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALXO
DateTimeSourceHeadlineSymbolCompany
30/04/202423:00GlobeNewswire Inc.ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerNASDAQ:ALXOALX Oncology Holdings Inc
25/04/202400:00GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
10/04/202407:30GlobeNewswire Inc.ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)NASDAQ:ALXOALX Oncology Holdings Inc
08/03/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
08/03/202408:03GlobeNewswire Inc.ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
06/03/202408:30GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
17/02/202410:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
17/02/202410:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
17/02/202410:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
06/01/202408:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
04/01/202408:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
04/01/202408:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
04/01/202408:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
04/01/202400:00GlobeNewswire Inc.ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
27/12/202308:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
14/11/202308:05GlobeNewswire Inc.ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
14/11/202308:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
02/11/202307:05GlobeNewswire Inc.ALX Oncology Announces November Investor Conference ParticipationNASDAQ:ALXOALX Oncology Holdings Inc
11/10/202307:05GlobeNewswire Inc.ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:ALXOALX Oncology Holdings Inc
06/10/202321:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
06/10/202321:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALXOALX Oncology Holdings Inc
05/10/202323:00GlobeNewswire Inc.ALX Oncology Announces Pricing of Public OfferingNASDAQ:ALXOALX Oncology Holdings Inc
05/10/202308:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
05/10/202308:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALXOALX Oncology Holdings Inc
05/10/202307:10GlobeNewswire Inc.ALX Oncology Announces Proposed Public OfferingNASDAQ:ALXOALX Oncology Holdings Inc
04/10/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
04/10/202301:03IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:ALXOALX Oncology Holdings Inc
03/10/202321:00GlobeNewswire Inc.ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerNASDAQ:ALXOALX Oncology Holdings Inc
03/10/202307:05GlobeNewswire Inc.ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerNASDAQ:ALXOALX Oncology Holdings Inc
20/09/202322:45InvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:ALXOALX Oncology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ALXO